| Chronic Obstructive Airway Disease
Stiolto Respimat vs Advair Diskus
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Stiolto Respimat vs Advair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAdvair has a higher rate of injection site reactions vs Stiolto Respimat based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Advair but not Stiolto Respimat, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stiolto Respimat
Advair
At A Glance
Oral inhalation
Once daily
LAMA/LABA
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Asthma
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Asthma 1 inhalation twice daily approximately 12 hours apart; adults and adolescents aged >=12 years may use 100/50, 250/50, or 500/50 strengths (max ADVAIR DISKUS 500/50 twice daily); pediatric patients aged 4 to 11 years use 1 inhalation of ADVAIR DISKUS 100/50 twice daily.
Chronic Obstructive Airway Disease 1 inhalation of ADVAIR DISKUS 250/50 twice daily approximately 12 hours apart.
Contraindications
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients
Adverse Reactions
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Most common (>=3%) Upper respiratory tract infection, pharyngitis, headaches, candidiasis mouth/throat, throat irritation, hoarseness/dysphonia, musculoskeletal pain, viral respiratory infections, nausea and vomiting, bronchitis, sinusitis, dizziness, muscle cramps and spasms
Serious Serious asthma-related events (hospitalizations, intubations, death), pneumonia in patients with COPD, cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma and cataracts
Postmarketing Arrhythmias (including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia), Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, paradoxical bronchospasm, immediate and delayed hypersensitivity reactions including anaphylaxis, agitation, depression, dysmenorrhea
Pharmacology
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
ADVAIR DISKUS combines fluticasone propionate, a synthetic trifluorinated corticosteroid that suppresses airway inflammation by acting on multiple cell types and mediators, and salmeterol, a selective long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Advair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Advair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Advair
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Stiolto Respimat.
No savings programs available for Advair.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Stiolto RespimatView full Stiolto Respimat profile
AdvairView full Advair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.